Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRTCNASDAQ:ISRGNYSE:PATH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRTCiRhythm Technologies$100.96+1.0%$105.45$55.92▼$128.52$3.17B1.45458,103 shs256,074 shsISRGIntuitive Surgical$482.74+0.3%$522.23$364.31▼$616.00$171.94B1.551.58 million shs1.62 million shsPATHUiPath$10.44+0.6%$11.65$9.38▼$20.95$5.76B1.0410.46 million shs11.97 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRTCiRhythm Technologies0.00%-1.11%-3.38%-6.80%-9.93%ISRGIntuitive Surgical0.00%-2.20%-1.98%-18.54%+31.77%PATHUiPath0.00%-4.09%-3.38%-19.84%-44.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRTCiRhythm Technologies0.9516 of 5 stars2.41.00.00.02.90.00.6ISRGIntuitive Surgical4.8326 of 5 stars4.44.00.04.03.52.51.9PATHUiPath2.9443 of 5 stars3.03.00.00.03.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRTCiRhythm Technologies 2.82Moderate Buy$119.7318.59% UpsideISRGIntuitive Surgical 2.70Moderate Buy$611.8126.74% UpsidePATHUiPath 2.00Hold$12.7221.83% UpsideCurrent Analyst Ratings BreakdownLatest ISRG, IRTC, and PATH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025PATHUiPathMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $11.004/14/2025ISRGIntuitive SurgicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$560.003/26/2025PATHUiPathRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$13.00 ➝ $13.003/26/2025PATHUiPathNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/18/2025ISRGIntuitive SurgicalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$707.00 ➝ $600.003/17/2025ISRGIntuitive SurgicalErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/17/2025ISRGIntuitive SurgicalTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$666.00 ➝ $605.003/14/2025PATHUiPathBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$16.00 ➝ $11.503/13/2025PATHUiPathRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $13.003/13/2025PATHUiPathCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.003/13/2025PATHUiPathUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$14.00 ➝ $10.00(Data available from 4/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRTCiRhythm Technologies$591.84M5.36N/AN/A$6.85 per share14.74ISRGIntuitive Surgical$8.35B20.59$6.36 per share75.93$46.41 per share10.40PATHUiPath$1.43B4.03N/AN/A$3.54 per share2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRTCiRhythm Technologies-$123.41M-$3.64N/AN/AN/A-19.14%-118.83%-11.34%5/1/2025 (Estimated)ISRGIntuitive Surgical$2.32B$6.4175.3163.275.8527.81%14.55%12.88%4/22/2025 (Estimated)PATHUiPath-$89.88M-$0.13N/AN/AN/A-6.49%-4.14%-2.82%5/27/2025 (Estimated)Latest ISRG, IRTC, and PATH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89N/AN/AN/A$153.39 millionN/A4/22/2025Q1 2025ISRGIntuitive Surgical$1.71N/AN/AN/A$2.19 billionN/A2/20/2025Q4 2024IRTCiRhythm Technologies-$0.29$0.01+$0.30-$0.04$158.30 million$164.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRTCiRhythm TechnologiesN/AN/AN/AN/AN/AISRGIntuitive SurgicalN/AN/AN/AN/AN/APATHUiPathN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRTCiRhythm Technologies9.006.276.12ISRGIntuitive SurgicalN/A4.073.22PATHUiPathN/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRTCiRhythm TechnologiesN/AISRGIntuitive Surgical83.64%PATHUiPath62.50%Insider OwnershipCompanyInsider OwnershipIRTCiRhythm Technologies0.68%ISRGIntuitive Surgical0.70%PATHUiPath22.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRTCiRhythm Technologies1,79031.41 million31.09 millionOptionableISRGIntuitive Surgical12,100356.18 million352.97 millionOptionablePATHUiPath4,010551.49 million426.65 millionOptionableISRG, IRTC, and PATH HeadlinesRecent News About These CompaniesMarshall Wace LLP Purchases 1,296,382 Shares of UiPath Inc. (NYSE:PATH)April 21 at 5:25 AM | marketbeat.comUiPath Inc. (NYSE:PATH) Receives Consensus Recommendation of "Hold" from AnalystsApril 21 at 4:48 AM | marketbeat.comLegal & General Group Plc Decreases Stock Position in UiPath Inc. (NYSE:PATH)April 21 at 4:04 AM | marketbeat.comUiPath Inc. (NYSE:PATH) Shares Bought by Wells Fargo & Company MNApril 21 at 3:43 AM | marketbeat.comWhat is DA Davidson's Forecast for UiPath FY2026 Earnings?April 19 at 8:15 AM | marketbeat.comDA Davidson Forecasts UiPath's FY2026 Earnings (NYSE:PATH)April 19 at 4:31 AM | americanbankingnews.comBridgewater Associates LP Boosts Stock Holdings in UiPath Inc. (NYSE:PATH)April 18 at 5:28 AM | marketbeat.comOntario Teachers Pension Plan Board Boosts Stake in UiPath Inc. (NYSE:PATH)April 18 at 5:28 AM | marketbeat.comAware Super Pty Ltd as trustee of Aware Super Invests $2.20 Million in UiPath Inc. (NYSE:PATH)April 18 at 5:19 AM | marketbeat.comMorgan Stanley Sticks to Its Hold Rating for UiPath (PATH)April 17, 2025 | markets.businessinsider.comUiPath Recognized as a Leader in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025April 17, 2025 | finance.yahoo.comMizuho Issues Pessimistic Forecast for UiPath (NYSE:PATH) Stock PriceApril 17, 2025 | marketbeat.comApril 16, 2025 | gurufocus.comUiPath's Oversold Status Triggers Cheap Buying Opportunity - Maintain BuyApril 16, 2025 | seekingalpha.comUiPath Inc. (NYSE:PATH) Stock Position Increased by Senvest Management LLCApril 16, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsApril 16, 2025 | fool.comMicrosoft Partners with UiPath on AI AutomationApril 15, 2025 | redmondmag.comUiPath price target lowered to $11 from $12 at MizuhoApril 15, 2025 | markets.businessinsider.comUiPath Inc. (NYSE:PATH) Shares Bought by Cerity Partners LLCApril 15, 2025 | marketbeat.comFranklin Resources Inc. Acquires 126,530 Shares of UiPath Inc. (NYSE:PATH)April 15, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 3,551,243 Shares of UiPath Inc. (NYSE:PATH)April 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeISRG, IRTC, and PATH Company DescriptionsiRhythm Technologies NASDAQ:IRTC$100.96 +1.01 (+1.01%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$100.90 -0.05 (-0.05%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Intuitive Surgical NASDAQ:ISRG$482.74 +1.40 (+0.29%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$476.94 -5.80 (-1.20%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.UiPath NYSE:PATH$10.44 +0.06 (+0.58%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$10.30 -0.14 (-1.34%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform's embedded AI, ML, and NLP capabilities improve decisioning and information processing; emulate human behavior allows organizations to address a myriad of use cases; emulate human behavior allows organizations to address a myriad of use cases; multi-tenant platform enterprise deployment with security and governance and Automation Cloud, which enables customers to begin automating without the need to provision infrastructure, install applications, or perform additional configurations; intuitive interface and low-code, drag-and-drop functionality; signed to enable people and automations to work together; and tracks, measures, and forecasts the performance of automations, enables customers to gain powerful insights and generate key performance indicators with actionable metric. It serves banking and financial services, healthcare, insurance, public sectors, manufacturing, retail, and telecom industries. The company was founded in 2005 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/14 - 04/18 Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
